The Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, estimated at USD 615.5 Mn in 2025, is expected to exhibit a CAGR of 3.2% and reach USD 767.3 Mn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
Global genetic chronic obstructive pulmonary disease (COPD) market is expected to witness significant growth over the forecast period, owing to factors such as new product launches and approvals by the key players. For instance, in June 2025, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., an Israel based multinational pharmaceutical company announced launch of the first generic version of PERFOROMIST twice daily, formoterol fumarate inhalation solution, 20 mcg/2 ml, indicated for the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema in the U.S. Moreover, in July 2025, AstraZeneca Plc., a science-led biopharmaceutical company, announced that it received approval for its Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) in the U.S. for maintenance therapy of patients with chronic obstructive pulmonary disease (COPD).
Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a positive impact on the global genetic chronic obstructive pulmonary disease (COPD) market, owing to its possible association with the COVID-19 infection and increasing research and development and product approval for the chronic obstructive pulmonary disease treatment. The chronic obstructive pulmonary disease treatment was used initially in first COVID wave to treat the coronavirus infection.
To know the latest trends and insights prevalent in this market, click the link below:
Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market: Key Developments
In March 2025, Grifols, a pharmaceutical company, launched an educational campaign: ‘Look into Genetic COPD’. The Look into Genetic COPD campaign enables patients with COPD in the U.S. to determine if they have Alpha-1 using a free AlphaKit test, which can be ordered directly on the website. The AlphaKit is shipped directly to the patient, who must then bring the test kit to their healthcare provider's office for testing. The quick and easy fingerstick test takes less than 10 minutes and the results are processed and delivered free of charge. A test for Alpha-1 is only required once in a lifetime.
Browse 26 Market Data Tables and 32 Figures spread through 178 Pages and in-depth TOC on “Global Genetic chronic obstructive pulmonary disease (COPD) Market”- Forecast to 2032, Global Genetic chronic obstructive pulmonary disease (COPD) Market, by Drug Class (Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Steroids, Antibiotics and Others), By Route of Administration (Oral and Nasal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
Moreover, increasing adoption of organic strategies such as research and development by key players in market is expected to drive the global genetic chronic obstructive pulmonary disease (COPD) market growth over the forecast period. For instance, in March 2025, the pharmaceutical business Pulmatrix, Inc. released encouraging top-line findings from its recently finished Phase Ib clinical research of PUR1800, a narrow-spectrum kinase inhibitor (NSKI) given as a dry powder for inhalation with iSPERSE for evaluation in patients with stable chronic obstructive pulmonary disease (COPD). For the treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease, PUR1800 is being developed (AECOPD). Patients with stable COPD were studied for initial safety and pharmacokinetics (PK).
Key Takeaways of the Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market:
- Global genetic chronic obstructive pulmonary disease (COPD) market is expected to exhibit a CAGR of 3.2% during the forecast period due to increasing license and agreement by market key players for the treatment genetic chronic obstructive pulmonary disease (COPD). For instance, in May 2025, the company RS BioTherapeutics, a company which is dedicated to providing advanced compounding solutions signed a license agreement with Synthonics Inc., a pharmaceutical company for the exclusive, global right to use Synthonics' metal coordinated cannabinoid in nebulized form for the treatment of pulmonary inflammatory disorders.
- Key players are focused on improving existing treatment options, research and development for new treatments, and increasing approval from regulatory bodies, which is expected to aid the market growth over the forecast period. For instance, in June 2025, the U.S. Food and Drug Administration (FDA) authorized Dupixent (dupilumab) for children with moderate-to-severe atopic dermatitis who are 6 months to 5 years old and whose condition is not well controlled by topical prescription medications. The European Medicines Agency is reviewing a regulatory filing for this age range, and submissions to regulatory bodies in other nations are progressing.
- Among regions, North America is estimated to account for the largest market share in the global genetic chronic obstructive pulmonary disease (COPD) market over the forecast period, owing to increasing prevalence of chronic obstructive pulmonary disease in the region. For instance, in November 2025, according to the data published by the Center for Disease Control and Prevention, in the U.S., age-adjusted death rates for COPD were significantly lower in 2025 compared with 2025 among U.S. men (57.0 per 100,000 in 1999 and 40.5 per 100,000 in 2025) and among U.S. women (35.3 per 100,000 in 1999 and 34.3 per 100,000 in 2025). Blacks and American Indian/Alaska Natives have the highest current asthma rates compared to other races and ethnicities. In 2025, Blacks (10.9%) were 42 percent more likely than Whites (7.7%) to have asthma. According to World Health Organization, asthma affected an estimated 262 million people in 2025 (1) and caused 455, 000 deaths globally.
- Major players operating in the global genetic chronic obstructive pulmonary disease (COPD) market include GSK Plc, AstraZeneca Plc, Merck (Sigma-Aldrich), Dey Pharma, Grifols, S.A., Teva Pharmaceutical Industries Ltd, Baxter, Boehringer Ingelheim International GmbH, Kamada Ltd, Takeda Pharmaceutical Company Limited, LFB SA, Abeona Therapeutics, Alnylam Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Kedrion S.p.A., and Arrowhead Pharmaceuticals, Inc.
Contact Us